Screening and Evaluation of Experimental Antiparasitic Drugs.
Abstract
The investigations undertaken during this report period included two primary and one secondary drug screening program in malaria, along with a primary and secondary drug screening program in African trypanosomiasis. The malarial system used Plasmodium berghei infected mice and Anopheles stephensi mosquitoes, while the African trypanosomiasis system used Trypanosoma rhodesiense infected mice. The first primary drug screen in malaria assessed compounds for blood schizonticidal activity. 5,375 three dose level tests were done with 1,261 exhibiting blood schizonticidal activity. The second primary screen in malaria assessed compounds for prophylactic antimalarial activity against sporozoite induced infections. 2,320 three dose level tests were performed to detect activity against sporozoites and/or exoerythrocytic stages. 161 compounds were curative with 116 of these being more active than primaquine. In the secondary drug screening program 49 compounds were found to be more active than quinine when administered via the oral and subcutaneous routes. The most active compounds were WR 223,146, WR 226,337 and WR 228,710. eighty-six compounds were tested against one or more of the following lines resistant to chloroquine, cycloguanil, dapsone, mefloquine, pyrimethamine, or quinine, respectively.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1979
- Accession Number
- ADA082935
Entities
People
- Arba L. Ager Jr.
Organizations
- University of Miami